Routine comprehensive care for children with sickle cell disease
- Zora R Rogers, MD
Zora R Rogers, MD
- Professor of Pediatrics
- The University of Texas Southwestern Medical Center
- Section Editor
- Donald H Mahoney, Jr, MD
Donald H Mahoney, Jr, MD
- Section Editor — Pediatric Hematology
- Professor of Pediatrics
- Baylor College of Medicine
The remarkable progress in the care of children with sickle cell disease (SCD) over the past several decades is directly attributable to the evolution of a standard of anticipatory guidance offered to families of affected children by most pediatric hematologists . Although there is a paucity of formal evidence-based standards of care, the National Institutes of Health (NIH) has released new evidence-based guidelines for the management of SCD [2,3]. While this document was developed with rigid evidence-based guideline methodology, many of the recommendations are moderate strength with low quality of evidence, usually based on expert consensus. This topic review represents a synthesis of the standards promoted by various professional societies [4-6], state and regional guideline efforts, as well as by more recent formal attempts to define quality care.
Each location at which clinical care is provided to children with SCD will have a different approach of how to implement the policies and patient education goals outlined below. Many providers use a roadmap or outline of care that is signed off at each visit or when a milestone is reached. In addition, formal assessment of these elements of care may serve as the basis for a quality improvement project [7-9]. However it is executed, it is beneficial to develop an outline of care that can be used to verify that planned educational and screening maneuvers have occurred. This is particularly true with respect to readiness for transition to adulthood education for medically complex patients.
The key elements of routine care and anticipatory guidance for a child with SCD are outlined here. Overviews of other aspects of the evaluation and management of SCD are discussed in separate topic reviews:
●Diagnosis – (See "Diagnosis of sickle cell disorders".)
●Clinical manifestations – (See "Overview of the clinical manifestations of sickle cell disease".)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447.
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
- Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines/ (Accessed on October 13, 2014).
- Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.
- American Academy of Pediatrics Council on Children with Disabilities. Care coordination in the medical home: integrating health and related systems of care for children with special health care needs. Pediatrics 2005; 116:1238.
- Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6.
- Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128:484.
- Crabtree EA, Mariscalco MM, Hesselgrave J, et al. Improving care for children with sickle cell disease/acute chest syndrome. Pediatrics 2011; 127:e480.
- Morrissey LK, Shea JO, Kalish LA, et al. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 2009; 52:369.
- Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.
- Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2012; :CD003427.
- American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.
- Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.
- Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108:2923.
- Morris CR. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol 2009; 84:234.
- Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189:727.
- DeVeber G, Kirkham F. Guidelines for the treatment and prevention of stroke in children. Lancet Neurol 2008; 7:983.
- Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.
- Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999; 21:518.
- Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am 2005; 19:917.
- Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med 2012; 9:88.
- Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269.
- Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.
- Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932.
- Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007; 21:118.
- Zemel BS, Kawchak DA, Ohene-Frempong K, et al. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res 2007; 61:607.
- Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics 2014; 134:465.
- Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102:171.
- McClellan AC, Luthi JC, Lynch JR, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 2012; 159:360.
- Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
- Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.
- Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.
- American Academy of Pediatrics. Immunization in special clinical circumstances. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove, Il 2015. p.68.
- Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood 2004; 104:336.
- Wise MS, Nichols CD, Grigg-Damberger MM, et al. Executive summary of respiratory indications for polysomnography in children: an evidence-based review. Sleep 2011; 34:389.
- American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.626.
- National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert Panel Report, 2014. www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines (Accessed on June 12, 2015).
- Folaranmi T, Rubin L, Martin SW, et al. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608.
- Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 2006; 17:2228.
- DeBaun MR, Telfair J. Transition and sickle cell disease. Pediatrics 2012; 130:926.
- NEWBORN SCREENING FOLLOW-UP
- First visit with an experienced SCD clinician
- - Timing
- - Laboratory testing
- - Medication
- Prophylactic penicillin
- Folic acid
- - Education and anticipatory guidance
- How to contact the sickle cell specialist
- ADDITIONAL EDUCATION
- Painful crises or events
- Acute chest syndrome
- Hydroxyurea, chronic transfusion, and stem cell transplantation
- FOLLOW-UP VISITS WITH A SCD EXPERT CLINICIAN
- Routine monitoring at all visits
- Additional age-specific recommendations
- - Zero to two years
- - Two to five years
- - Five years to adolescence
- - Older adolescents
- Other components of a comprehensive care program
- - Care plans
- - Other specialists for consultation
- SOCIETY GUIDELINE LINKS
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS